SequelSEC

Edesa Biotech, Inc. EDSA

Pharmaceutical Preparations · CIK 0001540159 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2021-09-30
Operating income
-$23.68M
Fiscal year ended 2021-09-30
Free cash flow
-$13.67M
Fiscal year ended 2021-09-30

Edesa Biotech, Inc. (EDSA) reported revenue of $0 and net income of -$13.34M for the fiscal year ended 2021-09-30. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Edesa Biotech, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Edesa Biotech, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302020-09-302018-09-302017-09-302016-09-302015-09-302014-08-31
Revenue$0$328.80K$211.85K$228.29K$1.27M$758.69K$372.13K
Cost of revenue$0$17.60K$133.32K$250.04K$818.57K$580.82K$469.15K
Gross profit$0$311.20K$78.53K-$21.76K$453.12K$177.86K-$97.02K
Operating income-$23.68M-$6.40M-$5.08M-$5.22M-$4.91M-$4.34M-$5.72M
Net income-$13.34M-$6.36M-$5.04M-$5.03M-$5.03M-$2.84M-$8.44M
Research & development$17.95M$3.33M$2.09M$1.97M$1.73M$1.03M$2.46M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableshares 8.83Mshares 7.96Mshares 7.58M
Pretax income-$13.34MUnavailable-$5.04M-$5.03M-$5.02M-$2.81M-$8.41M
Income tax expense$800$800$800$800$7.20K$36.80K$27.20K
Diluted EPSUnavailableUnavailableUnavailableUnavailable$-0.57$-0.36$-1.11
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$5.73M$3.38M$2.76M$2.94M$3.32M$3.23M$2.87M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Edesa Biotech, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302020-09-302018-09-302017-09-302016-09-302015-09-302014-08-31
Cash & equivalents$7.84M$7.21M$3.73M$4.57M$7.42M$3.96M$8.42M
Total assets$14.58M$10.76M$11.78M$7.72M$12.94M$10.39M$14.47M
Current assets$12.09M$8.10M$10.66M$6.76M$12.10M$9.87M$14.07M
Total liabilities$1.53M$1.65MUnavailableUnavailableUnavailable$2.38M$6.77M
Current liabilities$1.46M$1.53M$493.38K$320.95K$623.64K$2.38M$1.42M
Total equity incl. NCI$13.06M$6.63M$3.55M$7.40M$12.31M$8.01M$7.70M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailable$224.27K$68.11K$249.43K$557.28KUnavailable
Accounts receivable$3.30M$87.45K$41.25K$1.29K$85.81K$157.60K$56.58K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Edesa Biotech, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302020-09-302018-09-302017-09-302016-09-302015-09-302014-08-31
Operating cash flow-$13.66M-$4.99M-$4.62M-$4.70M-$4.51M-$4.41MUnavailable
Capital expenditures$6.15K$4.86K$382.81K$302.73K$402.27K$274.59K$279.06K
Investing cash flow-$6.15K$19.07K-$4.47M$1.69M$557.41K$122.47KUnavailable
Financing cash flow$14.17M$7.09M$8.77M$0$7.31M$106.78KUnavailable
Net change in cash$625.56K$2.18M-$345.43K-$2.85M$3.46M-$4.81M$563.20K
Stock-based compensation$3.20M$598.36K$154.31K$115.55K$259.38K$267.22K$956.63K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$118.79K$57.56K$188.00K$179.00K$149.56K$159.52K$158.31K

Derived

Edesa Biotech, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302020-09-302018-09-302017-09-302016-09-302015-09-302014-08-31
Free cash flow-$13.67M-$4.99M-$5.00M-$5.00M-$4.91M-$4.69MUnavailable
Gross marginUnavailable94.6%37.1%-9.5%35.6%23.4%-26.1%
Operating marginUnavailable-1946.7%-2397.1%-2288.6%-386.0%-571.9%-1536.7%
FCF marginUnavailable-1518.0%-2359.4%-2191.3%-385.9%-617.8%Unavailable
SBC / revenueUnavailable182.0%72.8%50.6%20.4%35.2%257.1%
Current ratio8.29x5.30x21.60x21.06x19.40x4.14x9.90x
Revenue YoY growth-100.0%Unavailable-7.2%-82.0%67.6%UnavailableUnavailable
Net marginUnavailable-1935.3%-2378.6%-2203.7%-395.2%-374.7%-2267.9%
R&D / revenueUnavailable1012.6%985.3%864.4%136.0%135.7%660.8%
CapEx / revenueUnavailable1.5%180.7%132.6%31.6%36.2%75.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EDSA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-Q · Filed 2026-02-13View SEC filing
10-K · Filed 2025-12-12View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-09-30

Difference 2476955 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.